PCK

PAINCHEK FPO [PCK]
PainChek Limited develops and commercialized mobile medical device applications that provides pain assessment for individuals in Australia, the United Kingdom, and internationally. The company offers PainChek, a clinically validated and regulatory cleared pain assessment technology that uses cameras in smartphones for a facial scan that is analyzed using facial recognition software to indicate the presence of pain. It serves patients suffering with dementia and pre-verbal infants; and the aged care, disability, home care, hospital, and infant sectors. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Healthcare · ASX Small Cap
$0.1000 +0.0%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when PCK triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track PCK — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Bollinger Bands are tightening — volatility is coiling up for a potential breakout
  • Drifting lower — down 4.8% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Low cash runway (3 quarters) - dilution risk
  • Moderate P/S ratio (6.1x)
  • Near 52-week low (1% of range)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 80% over the past year
  • Poor risk-adjusted returns — Sharpe of -1.5 means lots of volatility for not much reward
  • Altman Z-Score distress zone (1.12 < 1.81, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Deeply negative margins (-268%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • The bigger volume days are the down days — volume-weighted momentum is negative (-1.29%/day)
Ask Scout AI about PCK
"What's driving PCK today?" "How does PCK compare to peers?" "Key risks for PCK?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE US MedTech leader Karen Holzberger appointed CEO
NONE Final Director's Interest Notice
NONE CEO Transition

Recent ASX Announcements

2026-07-19 US MedTech leader Karen Holzberger appointed CEO PRICE SENSITIVE
2026-07-08 Final Director's Interest Notice
2026-07-06 CEO Transition PRICE SENSITIVE
2026-07-03 Notification of cessation of securities - PCK
2026-06-26 Change of Director's Interest Notice x5

Key Metrics

$20.9M
Market Cap
132K
Avg Volume
0.7x
Vol Ratio
$0.10 — $1.05
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-383.2%
ROE
-268.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 72%
LLeader vs LaggardlaggardRS: -17
IInstitutional SponsorshipweakInst: 2%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:PCK vs IDTPCK vs ADRPCK vs LDX
Scout Pro — Deeper Analysis for PCK
Try Pro free for 30 days
Share this analysis

Track PCK and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required